The Short Answers
- AACR abstracts must adhere to a 1,500-character limit (excluding title and author list), with strict formatting for headings, text, and references.
- Submissions open in January, with deadlines typically set for March–April (varies by meeting type). Late submissions are not considered.
- All human/animal studies require IRB/IACUC approval documentation uploaded during submission; failure to provide this is grounds for disqualification.
- Figures and tables must be embedded in the abstract text (not as attachments) and follow specific resolution/labeling rules.
- Conflicts of interest (COIs) must be disclosed at submission, including industry ties, patents, or grant funding—even if indirect.
Deep Dive: The Full Picture
The AACR submission guidelines are designed to standardize the presentation of oncology research while filtering for studies that meet the association’s criteria: originality, methodological soundness, and potential clinical impact. Unlike journal submissions where editors may offer feedback, AACR’s abstract review is binary—accept or reject—with no appeals process for formatting errors. This binary system forces applicants to treat the guidelines as non-negotiable. What distinguishes AACR’s process is its emphasis on pre-publication visibility. The association prioritizes abstracts that either: 1. Present unpublished data with high translational potential, or 2. Offer novel insights into mechanisms, therapies, or biomarkers that haven’t been widely disseminated elsewhere. Submissions that merely summarize published work—or repurpose data from other conferences—face higher rejection rates. The guidelines reflect this priority by mandating clear distinctions between "new" and "previously reported" findings in the abstract’s methodology section.The Context You Need
Historically, AACR’s abstract review was an opaque process, with acceptance rates fluctuating based on thematic focus (e.g., immunotherapy abstracts dominated in the 2010s). In 2018, the association overhauled its AACR submission guidelines to introduce a tiered review system: - Standard abstracts: Peer-reviewed by content experts. - Proffered papers: Invited for oral presentation (limited to ~10% of submissions). - Education sessions: Focused on training or methodological advances. This shift aimed to elevate the meeting’s scientific caliber while reducing the volume of "me-too" research. However, the trade-off was increased competition. Today, acceptance rates hover around 30–40% for standard abstracts, with proffered paper slots even more selective. The guidelines also now require structured abstracts—a departure from free-form narratives. Sections like "Translational Relevance" (mandatory since 2020) force applicants to articulate how their work bridges bench-to-bedside gaps. This requirement has led some researchers to argue that the guidelines favor applied over basic science, though AACR counters that all oncology research must ultimately demonstrate relevance to patient outcomes.The Mechanics
The submission portal (accessed via AACR’s website) enforces real-time validation of the AACR submission guidelines. For example: - Character counts are enforced per section (e.g., 250 characters for the "Results" heading). - Author lists must include all contributors in the order of their contribution, with corresponding authors marked distinctly. - References are limited to five citations, and only those directly supporting the abstract’s claims. One often-overlooked mechanic is the blinded review process. While abstracts are submitted with author names, the initial review is conducted anonymously. However, the guidelines explicitly state that high-profile senior authors may influence acceptance if their work is deemed transformative—though this is rarely disclosed post-review. Another critical mechanic is the figure/table policy. AACR permits one figure or table per abstract, but it must be: - Embedded in the text (not uploaded as a separate file). - Labeled as "Figure 1" (not "Panel A" or similar). - At least 300 DPI for clarity in printed programs. Failure to meet these technical specs can result in automatic rejection, even if the science is sound.Details That Change the Picture
The AACR submission guidelines include subtle rules that catch applicants off guard. For instance: - Title case is required for all headings (e.g., "Methods" not "methods"), but the abstract body must use sentence case for the first word after a colon. - Acronyms must be defined on first use, even if they’re standard in the field (e.g., "PD-1" requires "programmed death-1" in parentheses). - Clinical trial abstracts require trial registration numbers (e.g., NCT####) in the methodology section, regardless of phase. These details reflect AACR’s commitment to reproducibility and transparency—principles that have grown more stringent since the 2016 reproducibility crisis in cancer research. The association now flags abstracts lacking: - Statistical power calculations (for preclinical studies). - Patient demographics (for clinical trials, including race/ethnicity if applicable). - Uncertainty estimates (e.g., confidence intervals, not just p-values)."Too many researchers treat AACR’s guidelines as a checklist rather than a framework for communicating impact. The difference between an accepted and rejected abstract isn’t always the science—it’s whether the reviewer can immediately grasp why this work matters to their subfield." — Dr. Elena Martinez, AACR Abstract Review Committee Member (2022–2024)
| Requirement | Common Pitfall |
|---|---|
| IRB/IACUC approval documentation | Uploading a generic institutional approval letter instead of study-specific documentation. |
| Conflict of interest disclosure | Omitting indirect COIs, such as a collaborator’s patent held by their institution. |
| Translational relevance section | Generic statements like "This work has potential therapeutic implications" without specific pathways or targets. |
| Figure resolution | Submitting low-resolution images that appear pixelated in the final program. |
Conclusion
The AACR submission guidelines are not arbitrary—they’re a distillation of decades of lessons learned about what makes oncology research actionable. The most successful applicants treat these rules as an opportunity to refine their narrative, not just meet technical demands. For example, the "Translational Relevance" section isn’t a box to check; it’s a chance to align with AACR’s strategic priorities, such as precision medicine or cancer health disparities. That said, the guidelines are not static. AACR has signaled intentions to further integrate FAIR data principles (Findable, Accessible, Interoperable, Reusable) into future submissions, potentially requiring data deposition links for certain abstract types. Researchers should monitor updates and test drafts in the portal’s sandbox mode before finalizing submissions.Comprehensive FAQs
Q: Can I submit an abstract if my data is still under review at another conference?
A: Yes, but with caveats. AACR permits submissions of unpublished data presented elsewhere, provided you disclose the prior conference in the "Conflicts/Other Disclosures" section. However, abstracts that duplicate content from a published journal or another AACR meeting will be rejected. Prioritize submitting novel data to maximize acceptance chances.
Q: What happens if I miss the submission deadline?
A: There is no grace period. AACR’s portal locks at the deadline, and late submissions are automatically disqualified. Set reminders for the abstract submission deadline (typically March) and the final acceptance notification date (usually May–June). Some researchers use calendar alerts for both dates.
Q: Are there word limits for the "Translational Relevance" section?
A: No explicit word limit, but the section must fit within the 1,500-character abstract cap. A strong response typically requires 150–200 characters to convey clarity. Focus on one or two specific implications (e.g., "This kinase inhibitor shows synergy with pembrolizumab in PDX models, suggesting a rationale for combination trials in NSCLC") rather than broad claims.
Q: Can I submit multiple abstracts as the corresponding author?
A: Yes, but with restrictions. AACR allows one corresponding author per abstract, and each author can be listed as corresponding on up to three abstracts. Exceeding this limit may raise flags for "salami publishing" (splitting a single study into multiple abstracts). If submitting multiple abstracts, ensure each presents distinct data or hypotheses.
Q: How do I handle abstracts with international collaborators?
A: All authors must be listed with their full institutional affiliations, including country. For multi-country studies, specify which institution is primary (e.g., "Lead author: [Name], University of X, Country [X]; Collaborators: [Names], Institute Y, Country [Z]"). Ensure all co-authors grant permission to submit, as AACR requires electronic signatures from each during the process.
Q: What’s the best way to track changes after submitting?
A: AACR’s portal generates a submission ID upon upload. Save this ID and check the portal’s "My Submissions" tab for status updates. If you need to correct an error (e.g., a missing IRB document), contact AACR’s Abstract Submission Office within 48 hours of the deadline. After that window, corrections require resubmission as a new abstract.
